Cargando…
Circulating Endothelial Cells in Patients with Venous Thromboembolism and Myeloproliferative Neoplasms
BACKGROUND: Circulating endothelial cells (CEC) may be a biomarker of vascular injury and pro-thrombotic tendency, while circulating endothelial progenitor cells (CEP) may be an indicator for angiogenesis and vascular remodelling. However, there is not a universally accepted standardized protocol to...
Autores principales: | Torres, Cláudia, Fonseca, Ana Mafalda, Leander, Magdalena, Matos, Rui, Morais, Sara, Campos, Manuel, Lima, Margarida |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855326/ https://www.ncbi.nlm.nih.gov/pubmed/24339944 http://dx.doi.org/10.1371/journal.pone.0081574 |
Ejemplares similares
-
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
por: De Stefano, Valerio, et al.
Publicado: (2018) -
Trends and Inpatient Outcomes of Venous Thromboembolism-Related Admissions in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
por: Katiyar, Vatsala, et al.
Publicado: (2019) -
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
por: Barbui, Tiziano, et al.
Publicado: (2021) -
Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism
por: Lucijanic, Marko, et al.
Publicado: (2021) -
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
por: Huenerbein, Karlo, et al.
Publicado: (2020)